GoodRx Holdings, Inc. (GDRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GDRX currently has 105M outstanding shares. with significant dilution risk as 123M authorized shares could dilute existing holders by 117.9%. The company has diluted shareholders by 15.12% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 104.7M shares outstanding |
100M | 120M |
| Nov 04, 2025 |
10-Q filing | 105.5M shares outstanding |
110M | 120M |
| Aug 06, 2025 |
10-Q filing | 98.6M shares outstanding |
99M | 120M |
| May 07, 2025 |
10-Q filing | 100.3M shares outstanding |
100M | 120M |
| Feb 27, 2025 |
10-K filing | 106.7M shares outstanding |
110M | 120M |
| Nov 07, 2024 |
10-Q filing | 104.3M shares outstanding |
100M | 120M |
| Aug 08, 2024 |
10-Q filing | 98.6M shares outstanding |
99M | 120M |
| May 09, 2024 |
10-Q filing | 94.3M shares outstanding |
94M | 120M |
| Apr 05, 2024 |
S-3 filing: This is an S-3 filing for GoodRx Holdings, Inc. covering the offering of 99,983,317 shares of Class A common stock by selling securityholders. |
93M | 120M |
| Feb 29, 2024 |
10-K filing | 93.3M shares outstanding |
93M | 23M |
| Nov 21, 2023 |
8-K filing: GoodRx Holdings, Inc. repurchased 12,000,000 shares of its Class A common stock from Spectrum Equity at a price of $5.47 per share as part of its existing repurchase program. ($65.64M proceeds) |
92M | 23M |
| Nov 09, 2023 |
10-Q filing | 92.4M shares outstanding |
92M | 23M |
| Aug 09, 2023 |
10-Q filing | 84.1M shares outstanding |
84M | 23M |
| May 10, 2023 |
10-Q filing | 83.1M shares outstanding |
83M | 23M |
| Mar 01, 2023 |
10-K filing | 83.8M shares outstanding |
84M | 23M |
| Nov 09, 2022 |
10-Q filing | 82.5M shares outstanding |
82M | 23M |
| Aug 09, 2022 |
10-Q filing | 84.4M shares outstanding |
84M | 23M |
| May 10, 2022 |
10-Q filing | 82.7M shares outstanding |
83M | 23M |
| Mar 01, 2022 |
10-K filing | 86.2M shares outstanding |
86M | 23M |
| Nov 12, 2021 |
10-Q filing | 80.7M shares outstanding |
81M | 23M |
| Aug 12, 2021 |
10-Q filing | 75.4M shares outstanding |
75M | 23M |
| May 14, 2021 |
10-Q filing | 69.6M shares outstanding |
70M | 23M |
| Mar 12, 2021 |
10-K filing | 63.5M shares outstanding |
64M | 23M |
| Nov 12, 2020 |
10-Q filing | 43.9M shares outstanding |
44M | 23M |
| Sep 22, 2020 |
S-1/A filing: This S-1/A filing relates to an offering of Class A common stock with an assumed initial public offering price of $26.00 per share. |
N/A | 23M |
| Sep 14, 2020 |
S-1/A filing: This is an S-1/A filing for a common stock offering by GoodRx Holdings, Inc. and selling shareholders with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Barclays Capital Inc. acting as underwriters. Shares may be offered to the company's directors, officers, employees and business associates and other parties related to the company under the 'Directed Share Program'. |
N/A | 0 |